

89 Rec'd PCT/PTC

1996

89 Rec'd PCT/PTC TO 20 AUG 1996

FORM PCT/RO/132 (REV. 10-95) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER BWI-120CPUS
INTERNATIONAL APPLICATION NO. PCT/US95/02576		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 08/702525
INTERNATIONAL FILING DATE 02 March 1995 (02.03.95)		PRIORITY DATE CLAIMED 02 March 1994 (02.03.94)
TITLE OF INVENTION NOVEL FORMS OF T CELL COSTIMULATORY MOLECULES AND USES THEREFOR		
APPLICANT(S) FOR DO/EO/US Arlene H. SHARPE; Francescopaolo BORRIELLO; Gordon J. FREEMAN; & Lee M. NADLER		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendemnts has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (unexecuted) 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included: 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: 1) Published International Application (WO 95/23859); 2) International Search Report; 3) PCT Communication Form PCT/RO/132; 4) Response (dated 14 March 1996) to Communication Form PCT/RO/132 with attached Certificate of Corporate Authority; 5) Written Opinion (NO RESPONSE WAS FILED); 6) International Preliminary Examination Report; 7) Certificate of Express Mailing (EM558575965US); and 8) Postcard Receipt.		

08702525-083099

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.
PCT/US95/02576ATTORNEYS DOCKET NUMBER
BWI-120CPUS17. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO \$880.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) \$680.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$750.00

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1010.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$94.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$ 880

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	76 - 20 =	56	X \$22.00
Independent claims	21 - 3 =	18	X \$78.00

\$ 1232

\$ 1404

MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$250.00

\$ 0

TOTAL OF ABOVE CALCULATIONS =

\$ 3516

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

\$

SUBTOTAL =

\$ 3516

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE =

\$ 3516

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$

TOTAL FEES ENCLOSED =

\$ 3516

Amount to be:
refunded

\$

charged

\$

a. ☒ A check in the amount of \$ 3516 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

MANDRAGOURAS, Amy E.
Lahive & Cockfield
60 State Street
Boston, Massachusetts 02109phone: (617) 227-7400
fax: (617) 227-5941

SIGNATURE

Amy E. Mandragouras

NAME

36,207

REGISTRATION NUMBER

(National Phase of International App.: PCT/US95/02576)

In re the application of: Arlene H. SHARPE;
Francescopaolo BORRIELLO; Gordon J. FREEMAN;
and Lee M. NADLER

Serial No.:
(based on PCT/US95/02576)

Filed: Herewith

For: **NOVEL FORMS OF T CELL
COSTIMULATORY MOLECULES AND
USES THEREFOR**

Attorney Docket No.: BWI-120CPUS

Assistant Commissioner for Patents
BOX PCT
Washington, D.C. 20231


Certification Under 37 CFR 1.10

I hereby certify that the attached

Transmittal Letter (2 sheets); Declaration, Petition and Power of Attorney Document (5 sheets) (unexecuted); Published International Application (WO 95/23859) (111 sheets); International Search Report (5 sheets); PCT Communication Form PCT/RO/132 (1 sheet); Response (dtd 14 March 1996) to Communication Form PCT/RO/132 w/attached Certificate of Corporate Authority; (2 sheets); Written Opinion (NO RESPONSE WAS FILED) (6 sheets); International Preliminary Examination Report (6 sheets); check for \$3,516.00 (representing filing fees based on large entity status); and postcard receipt.

are being deposited by me with the United States Postal Service "Express Mail Post Office to Addressee" service, Mailing Label No. EM558575965US, under 37 CFR 1.10 on the date indicated below and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

Name: Angelica N. Martinez


Signature

LAHIVE & COCKFIELD

COUNSELLORS AT LAW
SIXTY STATE STREET
BOSTON, MASSACHUSETTS 02109-1875

TELEPHONE (617) 227-7400

FAX (617) 227-5941

lc@lahcoc.com

MARK A. KURISKO
BETH E. ARNOLD
JEAN M. SILVERI
CAROLYN G. d'AGINCOURT
PETER J. RAINVILLE

OF COUNSEL
JEREMIAH LYNCH

PATENT AGENT
MATTHEW P. VINCENT, Ph.D.

TECHNICAL SPECIALISTS
CATHERINE J. KARA, Ph.D.
MARK D. RUSSETT
ISABELLE M. CLAUSS, Ph.D.
IVANA MARAVIC-MAGOVCEVIC, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
SONIA K. GUTERMAN, Ph.D.

14 March 1996

Box PCT

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Attn: RO/US

Re: International Application No. PCT/US95/02576
Novel Forms of T Cell Costimulatory Molecules and Uses Therefor
Applicants: Brigham & Women's Hospital; Dana-Farber Cancer Institute; Arlene H. Sharpe; Francescopaolo Borriello; Gordon J. Freeman; and Lee M. Nadler
International Filing Date: 02 March 1995
Our Reference: BWI-120CPPC

Dear Sir:

Responsive to the Communication Form PCT/RO/132 mailed from the United States Receiving Office on 24 January 1996, enclosed for filing with the above-identified application is a Certificate of Corporate Authority authorizing Julia D. Hart to sign on behalf of Dana-Farber Cancer Institute in all patent-related matters.

In view of this document, it is believed that the General Power of Attorney executed by Julia D. Hart submitted 9 November 1995 in the above-referenced application is proper.

Respectfully submitted,

Amy E. Mandragouras
Attorney for Applicant

Certificate of Express Mailing	
Express Mail No.: EM 277 519 424 US	
I hereby certify that this paper or fee is being deposited with the United States Postal Service as Express Mail on the date indicated below and is addressed to Box PCT, Commissioner of Patents and Trademarks, Washington, DC 20231	
14 March 1996 Date of Deposit	By: <u>Ariel I. Collazo</u> Ariel I. Collazo

AEM/IMC/jmg
Enclosure